Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
Open Access
- 1 May 1999
- journal article
- clinical trial
- Published by Elsevier
- Vol. 10 (5) , 553-560
- https://doi.org/10.1023/a:1026418831238
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.Journal of Clinical Oncology, 1997
- Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.Journal of Clinical Oncology, 1996
- Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxicAnnals of Oncology, 1996
- A multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTCAnnals of Oncology, 1996
- Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.Journal of Clinical Oncology, 1995
- Coping with toxicities of docetaxel (TaxotereTM)Annals of Oncology, 1993
- Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapyThe American Journal of Medicine, 1987
- Reporting results of cancer treatmentCancer, 1981
- Risk Factors for Doxorubicin-lnduced Congestive Heart FailureAnnals of Internal Medicine, 1979
- Serial Assessment of Doxorubicin Cardiotoxicity with Quantitative Radionuclide AngiocardiographyNew England Journal of Medicine, 1979